Early termination of SAFA fusion protein contract with Yuhan, strategic shift
Early termination of the SAFA-based fusion protein technology license and joint research contract with Yuhan Corporation effective May 4, 2026.
Termination by mutual agreement with no obligation to refund upfront payments already received.
Decision driven by R&D strategy and priority adjustment to respond to rapidly changing global markets.
Future focus on REMAP platform for pipeline alignment with trends such as ADC and AOC.
KOSDAQ Filing Information
Major Management Matters Related to Investment Decision (Yuhan Corporation, Early Termination of SAFA-Based Fusion Protein Technology License and Joint Research and Development Contract)